Coherus Terminates its License Agreement with Innovent for Byvasda (biosimilar, bevacizumab)
- Coherus has terminated its license agreement with Innovent for Byvasda, a biosimilar referencing bevacizumab. Coherus will return the rights to Innovent
- In Jan 2020, Coherus has entered into a license agreement with Innovent for Avastin biosimilar where Coherus got the development & commercialization rights of CHS-305 in the US & Canada
- Byvasda has been approved in China for patients with lung & colorectal cancers in June 2020 while the NMPA has expanded the indication list for the biosimilar to include unresectable HCC when paired with sintilimab therapy in June 2021. The US FDA’s review of the BLA for Cimerli (biosimilar, ranibizumab) is expected to be completed by Aug 2, 2022
Ref: The Center For Biosimilars | Image: Coherus
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.